Abstract:Phasing of heterozygous alleles is critical for interpretation of cis -effects of disease-relevant variation. For population studies, phase is often inferred from external data but read-based phasing approaches that span long genomic distances would be more accurate because they enable both genotype and phase to be obtained from a single dataset. To demonstrate how read-based phasing can provide functional insights, we sequenced 477 individuals with Cystic Fibrosis (CF) using linked-read sequencing. We benchmark read-based phasing with different short- and long-read sequencing technologies, prioritize linked-read technology as the most informative and produce a benchmark phase call set from reference sample HG002 for the community. The 477 samples display an average phase block N50 of 4.39 Mb. We use these samples to construct a graph representation of CFTR haplotypes, which facilitates understanding of complex CF alleles. Fine-mapping and phasing of the chr7q35 trypsinogen locus associated with CF meconium ileus demonstrates a 20 kb deletion and a PRSS2 missense variant p.Thr8Ile (rs62473563) independently contribute to meconium ileus risk (p=0.0028, p=0.011, respectively) and are PRSS2 pancreas eQTLs (p=9.5e-7 and p=1.4e-4, respectively), explaining the mechanism by which these polymorphisms contribute to CF. Phase enables access to haplotypes that can be used for genome graph or reference panel construction, identification of cis -effects, and for understanding disease associated loci. The phase information from linked-reads provides a causal explanation for variation at a CF-relevant locus which also has implications for the genetic basis of non-CF pancreatitis to which this locus has been reported to contribute. ### Competing Interest Statement DMC received an honorarium for teaching module development for Vertex Pharmaceuticals. NM is doing contract research trials for Vertex Phaemaceuticals and Abbvie. ALS has received speaking fees for educational programs sponsored by Vertex Pharmaceuticals. BSQ has received speaker fees from Vertex Pharmaceuticals and has served as site PI for several Vertex-sponsored clinical trials. WML is a study investigator for Vertex Pharmaceuticals. ET and FR act as consultants for Vertex Pharmaceuticals. MS participated in Vertex clinical trials and received payment for education modules. SM, AC, JG, FL, BT, WWLS, JW, ZW, RVP, KK, AH, NP, JA, CW, GCM, SB, DA, EB, CB, MC, AP, MP, RVW, DH, MJS, ET, PW, LS, FR, and LJS have no conflicts of interest. * CF : cystic fibrosis CFTR : cystic fibrosis transmembrane conductance WGS : whole genome sequencing GWAS : genome-wide association studies MI : meconium ileus LD : linkage disequilibrium PacBio : Pacific Biosciences 10XG : 10x Genomics CGMS : Canadian CF Gene Modifier Study Consortium CLR : PacBio continuous long-reads CCS : PacBio circular consensus sequence VCF : variant call format GIAB : Genome in a Bottle HMW : high molecular weight TCAG : The Centre for Applied Genomics GTEx : Genotype-Tissue Expression ER : endoplasmic reticulum SRP : signal recognition particle QC : quality control

Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences

Whole-Exome Sequencing Identified CFTR Variants in Two Consanguineous Families in China

Multisite Verification of a Targeted CFTR Polymerase Chain Reaction/Capillary Electrophoresis Assay That Evaluates Pathogenic Variants Across Diverse Ethnic and Ancestral Groups

Complete CFTR Gene Sequencing in 5,058 Individuals with Cystic Fibrosis Informs Variant-Specific Treatment.

Accounting for Population Structure in Genetic Studies of Cystic Fibrosis.

Genetic analysis and functional study of novel CFTR variants in Chinese children with cystic fibrosis

Systematic Estimation of Cystic Fibrosis Prevalence in Chinese and Genetic Spectrum Comparison to Caucasians

Genomic Rearrangements in the Cftr Gene: Extensive Allelic Heterogeneity and Diverse Mutational Mechanisms

Exploring Turkey's mosaic of novel variants and complex alleles in cystic fibrosis genetics

DOP57 Cystic fibrosis risk variants confer a protective effect against Inflammatory Bowel Disease in large-scale exome sequencing analysis

Rare variant contribution to human disease in 281,104 UK Biobank exomes

Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia

Exome sequencing and analysis of 454,787 UK Biobank participants

Cystic fibrosis risk variants confer protection against inflammatory bowel disease

Regionally enriched rare deleterious exonic variants in the UK and Ireland

Population Characteristics of the Spectrum and Frequencies of CFTR Gene Mutations in Patients with Cystic Fibrosis from the Republic of Bashkortostan (Russia)

High-quality Read-Based Phasing of Cystic Fibrosis Cohort Informs Genetic Understanding of Disease Modification

Compound heterozygous CFTR variants (Q1352H and 5T; TG13) in a Chinese patient with cystic fibrosis

Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes

CFTR pathogenic variants spectrum in a cohort of Mexican patients with cystic fibrosis

High Quality Phasing Using Linked-Read Whole Genome Sequencing of Patient Cohorts Informs Genetic Understanding of Complex Traits